Patent: 10,849,919
✉ Email this page to a colleague
Summary for Patent: 10,849,919
| Title: | Cladribine regimen for treating progressive forms of multiple sclerosis |
| Abstract: | Specific oral dosings, specific oral dosage forms, and/or specific oral dose regimens including Cladribine can be effective for the treatment of progressive forms of Multiple Sclerosis, especially Primary Progressive Multiple Sclerosis and/or Secondary Progressive Multiple Sclerosis. Methods of treatment can be based on specific oral dosings, specific oral dosage forms, and/or specific oral dose regimens including Cladribine. |
| Inventor(s): | Dangond Fernando, Dotzauer Matthias |
| Assignee: | Merck Patent GmbH |
| Application Number: | US16199119 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 10,849,919 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,849,919
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | BETASERON | interferon beta-1b | For Injection | 103471 | July 23, 1993 | 10,849,919 | 2038-11-23 |
| Biogen Inc. | AVONEX | interferon beta-1a | For Injection | 103628 | May 17, 1996 | 10,849,919 | 2038-11-23 |
| Biogen Inc. | AVONEX | interferon beta-1a | Injection | 103628 | May 28, 2003 | 10,849,919 | 2038-11-23 |
| Biogen Inc. | AVONEX | interferon beta-1a | Injection | 103628 | February 27, 2012 | 10,849,919 | 2038-11-23 |
| Emd Serono, Inc. | REBIF | interferon beta-1a | Injection | 103780 | March 07, 2002 | 10,849,919 | 2038-11-23 |
| Emd Serono, Inc. | REBIF | interferon beta-1a | Injection | 103780 | December 17, 2004 | 10,849,919 | 2038-11-23 |
| Emd Serono, Inc. | REBIF | interferon beta-1a | Injection | 103780 | December 21, 2012 | 10,849,919 | 2038-11-23 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
